Alumis Inc. (NASDAQ:ALMS) Short Interest Up 25.3% in March
by Teresa Graham · The Cerbat GemAlumis Inc. (NASDAQ:ALMS – Get Free Report) saw a significant growth in short interest in March. As of March 31st, there was short interest totaling 11,230,693 shares, a growth of 25.3% from the March 15th total of 8,963,277 shares. Based on an average trading volume of 2,042,725 shares, the short-interest ratio is presently 5.5 days. Approximately 14.9% of the company’s shares are short sold.
Alumis Trading Up 5.5%
ALMS stock opened at $24.16 on Thursday. Alumis has a twelve month low of $2.76 and a twelve month high of $30.60. The company has a market capitalization of $3.07 billion, a P/E ratio of -7.90 and a beta of -0.64. The firm has a 50 day simple moving average of $25.68 and a 200-day simple moving average of $16.16.
Alumis (NASDAQ:ALMS – Get Free Report) last released its quarterly earnings results on Thursday, March 19th. The company reported ($0.95) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.05). Alumis had a negative return on equity of 116.97% and a negative net margin of 1,011.75%.The company had revenue of $1.93 million for the quarter, compared to analyst estimates of $2.75 million. On average, research analysts predict that Alumis will post -8.51 EPS for the current year.
Wall Street Analysts Forecast Growth
Several equities research analysts have recently issued reports on the stock. UBS Group reissued an “outperform” rating on shares of Alumis in a research report on Tuesday, January 6th. Wells Fargo & Company increased their price objective on shares of Alumis from $17.00 to $39.00 and gave the company an “overweight” rating in a research report on Tuesday, January 6th. Morgan Stanley increased their price objective on shares of Alumis from $33.00 to $38.00 and gave the company an “overweight” rating in a research report on Friday, March 20th. Loop Capital set a $37.00 price objective on shares of Alumis in a research report on Wednesday, January 21st. Finally, HC Wainwright lowered their price objective on shares of Alumis from $40.00 to $25.00 and set a “buy” rating for the company in a research report on Monday, March 30th. One equities research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $38.60.
Read Our Latest Stock Analysis on ALMS
Hedge Funds Weigh In On Alumis
Large investors have recently added to or reduced their stakes in the company. Russell Investments Group Ltd. lifted its stake in Alumis by 320.9% during the third quarter. Russell Investments Group Ltd. now owns 6,419 shares of the company’s stock worth $26,000 after purchasing an additional 4,894 shares during the last quarter. New York State Common Retirement Fund lifted its stake in Alumis by 173.7% during the second quarter. New York State Common Retirement Fund now owns 11,767 shares of the company’s stock worth $35,000 after purchasing an additional 7,467 shares during the last quarter. CWM LLC lifted its stake in Alumis by 1,028.7% during the third quarter. CWM LLC now owns 10,384 shares of the company’s stock worth $41,000 after purchasing an additional 9,464 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its stake in Alumis by 26.1% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,724 shares of the company’s stock worth $46,000 after purchasing an additional 979 shares during the last quarter. Finally, BNP Paribas Financial Markets grew its position in shares of Alumis by 104.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 11,770 shares of the company’s stock valued at $47,000 after buying an additional 6,027 shares during the last quarter.
Alumis Company Profile
Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.